Immix Biopharma

IMMX Rare disease Lead: Phase 1 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-25

Catalyst timeline

NXC-201 commercial launch1H 2027NXC-201 commercial launch, 1H 2027, routine
NXC-201 Ph2 toplinemid-2027NXC-201 Ph2 topline, mid-2027, thesis-defining
NXC-201 BLA filingmid-2027NXC-201 BLA filing, mid-2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

NXC-201

Cell Target: BCMA

Relapsed/Refractory AL Amyloidosis Phase 1 Phase1/2 trial Memorial Sloan Kettering Cancer Center NCT06097832

Technology platforms

N-GENIUS · Hadasit

Cell engineering platform with EXPAND technology and COBRA binder scaffold generation; produces CAR-T candidates targeting BCMA and other targets for hematologic, neurologic, rheumatologic, vascular and other serious diseases

Targets: BCMA

N-GENIUS

Proprietary CAR-T cell therapy development platform that produced NXC-201, a next-generation CAR-T designed to treat AL Amyloidosis and other serious diseases

Biotech Distilled coverage (3)

2026-09-29 UPDATE: Immix Biopharma (IMMX) - The Data Holds, the Clock Slips 🔒 Paid
2026-05-21 UPDATE: Immix Biopharma (IMMX) — The 95% CR Lands, and the Dilution Gap Closes Before It Opens 🔒 Paid
2026-05-12 Immix Biopharma (IMMX) - Scientific Deep Dive for NXC-201 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.